Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01000974
Other study ID # 112957
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 18, 2010
Est. completion date July 17, 2013

Study information

Verified date June 2018
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate vaccine and the licensed monovalent Hib vaccine ActHIB as well as the licensed combination product Pentacel in infants at 2, 4, 6 and 15-18 months of age. This study is designed with a primary and a booster phase.


Description:

This protocol posting has been updated following protocol amendment 3, dated 12 April 2011. The impacted section is: Eligibility Criteria (Exclusion criteria).


Recruitment information / eligibility

Status Completed
Enrollment 4003
Est. completion date July 17, 2013
Est. primary completion date November 18, 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 12 Weeks
Eligibility Inclusion Criteria:

- Subjects for whom the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR[s]) can and will comply with the requirements of the protocol (e.g., completion of the diary card, return for follow-up visits).

- A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.

- Written informed consent obtained from the subject's parent/LAR.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

- Born after a gestation period of minimum 36 weeks.

- Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrollment.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.

- Planned administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine and until 30 days after the booster dose.

- Previous vaccination against Haemophilus influenzae type b, diphtheria, tetanus, pertussis, Pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.

- History of Haemophilus influenzae type b, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus, and hepatitis B diseases.

- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including dry natural latex rubber.

- Major congenital defects or serious chronic illness.

- History of any neurologic disorders or seizures.

- Acute disease at time of enrollment. All vaccines can be administered to persons with a minor illness.

- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

- Concurrent participation in another clinical study, up to 30 days prior to study entry or at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

- Child in care.

- History of intussusception.

- History of uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.

- History of Severe Combined Immunodeficiency Disease.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)
Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
ActHIB™
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Pentacel™
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Pediarix™
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Prevnar 13™
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Rotarix™
Two oral doses in primary epoch at 2 and 4 months of age
Engerix™-B
Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
Infanrix™
One dose in the booster epoch at 15-18 months of age as intramuscular injection

Locations

Country Name City State
United States GSK Investigational Site Amarillo Texas
United States GSK Investigational Site Anaheim California
United States GSK Investigational Site Antioch California
United States GSK Investigational Site Bardstown Kentucky
United States GSK Investigational Site Benton Arkansas
United States GSK Investigational Site Boulder Colorado
United States GSK Investigational Site Bountiful Utah
United States GSK Investigational Site Canton Ohio
United States GSK Investigational Site Charleston South Carolina
United States GSK Investigational Site Cincinnati Ohio
United States GSK Investigational Site Cleveland Ohio
United States GSK Investigational Site Colorado Springs Colorado
United States GSK Investigational Site Daly City California
United States GSK Investigational Site Dayton Ohio
United States GSK Investigational Site Dothan Alabama
United States GSK Investigational Site Erie Pennsylvania
United States GSK Investigational Site Fall River Massachusetts
United States GSK Investigational Site Fargo North Dakota
United States GSK Investigational Site Fayetteville Arkansas
United States GSK Investigational Site Fort Worth Texas
United States GSK Investigational Site Fountain Valley California
United States GSK Investigational Site Fremont California
United States GSK Investigational Site Fresno California
United States GSK Investigational Site Greenville Pennsylvania
United States GSK Investigational Site Hayward California
United States GSK Investigational Site Hermitage Pennsylvania
United States GSK Investigational Site Honolulu Hawaii
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Huntington Beach California
United States GSK Investigational Site Jonesboro Arkansas
United States GSK Investigational Site Layton Utah
United States GSK Investigational Site Little Rock Arkansas
United States GSK Investigational Site Louisville Kentucky
United States GSK Investigational Site Madison Wisconsin
United States GSK Investigational Site Marietta Georgia
United States GSK Investigational Site Marshfield Wisconsin
United States GSK Investigational Site Mineola New York
United States GSK Investigational Site Nampa Idaho
United States GSK Investigational Site Oakland California
United States GSK Investigational Site Omaha Nebraska
United States GSK Investigational Site Orange City Florida
United States GSK Investigational Site Redwood City California
United States GSK Investigational Site Roseville California
United States GSK Investigational Site Roy Utah
United States GSK Investigational Site Sacramento California
United States GSK Investigational Site Sacramento California
United States GSK Investigational Site Saint Paul Minnesota
United States GSK Investigational Site Salt Lake City Utah
United States GSK Investigational Site San Jose California
United States GSK Investigational Site Santa Clara California
United States GSK Investigational Site Santa Rosa California
United States GSK Investigational Site South Jordan Utah
United States GSK Investigational Site Stevensville Michigan
United States GSK Investigational Site Sugar Land Texas
United States GSK Investigational Site Syracuse New York
United States GSK Investigational Site Syracuse Utah
United States GSK Investigational Site Tulsa Oklahoma
United States GSK Investigational Site Utica New York
United States GSK Investigational Site Vallejo California
United States GSK Investigational Site Waipio Hawaii
United States GSK Investigational Site Walnut Creek California
United States GSK Investigational Site West Covina California
United States GSK Investigational Site Woodstock Georgia

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (=) 0.15 Microgram Per Milliliter (µg/mL) and = 1.0 µg/mL Non-inferiority of Hiberix to ActHIB, each co-administered with Pediarix, Prevnar13 and Rotarix following 3 primary doses in terms of immune response to PRP (Anti-PRP= 0.15 µ g/ml and =1.0 µg/mL). At 1 month after last dose of primary vaccination
Primary Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations = 0.1 International Units Per Milliliter (IU/mL) Non-inferiority of Pediarix co-administered with Hiberix, Prevnar13 and Rotarix compared to Pediarix co-administered with ActHIB, Prevnar13 and Rotarix following 3 primary vaccine doses in terms of immune response to Diphtheria, Tetanus. At 1 month after last dose of primary vaccination
Primary Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL). At 1 month after last dose of primary vaccination
Primary Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody Concentrations Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL. At 1 month after last dose of primary vaccination
Primary Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody Concentrations Antibody concentrations against S.pneumoniae were given as geometric mean concentrations (GMCs) expressed as microgram per milliliter (µg/mL). At 1 month after last dose of primary vaccination
Primary Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Seroresponse (95%) was defined as the number of subjects showing a concentration above a threshold that leads to 95% seroresponse in the ActHIB group. At 1 month after last dose of primary vaccination
Primary Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off Value The cut-off value was defined as a concentration = 8 ED50 (ED50 is the concentration at which the protein exhibits 50% of its maximum activity).
The polio testing which started at the Biomnis laboratory was stopped because the polio virus micro-neutralization assays were found to be not in line with the quality standards defined in GSK Biologicals' SOPs. As a result, polio testing was restarted at the GSK laboratory and the results were uploaded into the clinical database.
At 1 month after last dose of primary vaccination
Primary Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations = 1.0 µg/mL Non-inferiority of a booster dose of Hiberix co-administered with Infanrix in subjects 15-18 months of age who received 3 primary vaccine doses of Hiberix to a booster dose of ActHIB co-administered with Infanrix in subjects of 15-18 months of age who received 3 primary vaccine doses of ActHIB in terms of immune response to PRP At 1 month after booster vaccination
Secondary Anti-protein-D (Anti-D) and Anti-protein-T (Anti-T) Antibody Concentrations Antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as International Units per milliliter (IU/mL). At 1 month after last dose of primary vaccination
Secondary Number of Subjects With Any Solicited Local Symptoms Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade. During a 4-day follow-up period (Days 0-3) following any vaccination
Secondary Number of Subjects With Any Solicited General Symptoms Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Rectal temperature equal to or above (=) 38 degrees Celsius (°C). During a 4-day follow-up period (Days 0-3) following any vaccination
Secondary Number of Subjects With Any Unsolicited Adverse Events (AEs). An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. During the 31-day (Day 0-Day 30) follow-up period after primary vaccination
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. From Day 0 until 6 months following the last primary dose
Secondary Number of Subjects With AEs of Specific Interest (AESIs) An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration. From Day 0 until 6 months following the last primary dose or the receipt of the booster vaccination, whichever comes first
Secondary Number of Subjects With Seroresponse (90%) to Anti-PT, Anti-PRN and Anti-FHA Seroresponse (90%) was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group. At 1 month after last dose of primary vaccination
Secondary Number of Subjects With Anti-PT, Anti-PRN and Anti-FHA Antibody Concentrations = 5 EL.U/mL Seroresponse was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group. At 1 month after last dose of primary vaccination
Secondary Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations = 0.15 µg/mL and = 1.0 µg/mL Evaluation of persistence of anti-PRP antibodies induced by three primary vaccine doses of Hiberix, and ActHIB, each co-administered with Pediarix, Prevnar 13 and Rotarix, or Pentacel co-administered with Engerix-B, Rotarix and Prevnar 13 prior to the booster dose of Hiberix, ActHIB or Pentacel at 15-18 months of age and evaluation of immunogenicity of a booster dose of Hiberix co-administered with Infanrix, ActHIB co-administered with Infanrix and Pentacel in terms of the percentage of subjects with anti-PRP concentrations =0.15 µg/mL, =1.0 µg/mL and GMCs one month after the booster dose. Prior to the booster vaccination and 1 month after the booster vaccination
Secondary Anti-Hepatitis B (Anti-HBs) Antibody Concentrations Antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressedas milli-international units per milliliter (mIU/mL). At 1 month after last dose of primary vaccination
Secondary Number of Subjects With S.Pneumoniae Antibody Concentrations = 0.05 µg/mL, = 0.2 µg/mL and =1.0 µg/mL Evaluation of immunogenicity of a 3-dose primary vaccination course of Prevnar 13 co-administered with Hiberix, Rotarix and Pediarix, of Prevnar 13 co-administered with ActHIB, Rotarix and Pediarix and of Prevnar 13 co-administered with Pentacel, Rotarix and Engerix-B in terms of S.pneumoniae GMCs and antibody concentrations = 0.05µg/mL, = 0.2 µg/mL, = 1.0 µg/mL at one month after the last dose of primary vaccination. At 1 month after the last dose of primary vaccination
Secondary Antibody Titers for Poliovirus Types 1, 2 and 3 Antibody titers were given as geometric mean titers(GMTs). At 1 month after last dose of primary vaccination
Secondary Number of Subjects With Anti-HBs Antibody Concentrations Greater Than or Equal to Cut-off Values The cut-off values were defined as a concentration= 3.3 mIU/mL (seropositivity) and = 10 mIU/mL (seroprotection). At 1 month after last dose of primary vaccination
Secondary Anti-polyribosylribitol Phosphate (PRP) Antibody Concentrations Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL). Prior to the booster vaccination and 1 month after the booster vaccination
Secondary Anti-Hepatitis B (Anti-HBs) Antibody Concentrations =10.0 mIU/mL and =6.2 mIU/mL Antibody concentrations were expressed as geometric mean concentrations (GMCs) and expressed as milli-international units per milliliter (mIU/mL). Prior to the booster vaccination
Secondary Number of Subjects With Anti-HB Antibody Concentrations =10.0 mlU/mL and =6.2mLU/mL The cut-off values were defined as a concentration= 6.2 mIU/mL (seropositivity) and = 10 mIU/mL (seroprotection). Prior to booster vaccination
Secondary Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations = 5 EL.U/mL Evaluation of persistence of anti-PT, anti-FHA and anti-PRN antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-PT, anti-FHA and anti- PRN antibodies. Prior to the booster vaccination and 1 month after the booster vaccination
Secondary Anti-poliovirus Types 1, 2, and 3 Antibody Titres and Titres = 8 Antibody concentrations were tabulated as geometric mean titers (GMTs) and expressed as titers. Prior to the booster vaccination
Secondary Number of Subjects With Anti-Polio-1,2,3 Antibody Titers = 8 Anti-polio 1,2,3 antibody titers greater or equal to the cut off value were calculated. Prior to booster vaccination
Secondary Number of Subjects With Anti-D and Anti-T Antibody Concentrations = 0.1 IU/mL and =1.0 IU/mL, Respectively. Evaluation of persistence of anti-D, anti-T antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-D and anti-T antibodies. Prior to the booster vaccination and 1 month after the booster vaccination
Secondary Number of Subjects With Any Solicited Local Symptoms Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade. Within 4 days (Days 0-3) following the booster dose
Secondary Number of Subjects With Any Solicited General Symptoms Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Axillary temperature equal to or above (=) 38 degrees Celsius (°C). Within 4 days (Days 0-3) following the booster dose
Secondary Number of Subjects With AEs of Specific Interest (AESIs) An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration. From booster dose until 6 months following receipt of the booster dose
Secondary Number of Subjects With Any Unsolicited Adverse Events (AEs). An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Within 31 days (Day 0 to Day 30) following the booster dose
Secondary Number of Subjects With Serious Adverse Events (SAEs) SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. From the booster dose until 6 months following receipt of the booster dose
Secondary Anti-FHA, Anti-PRN and Anti-PT Antibody Concentrations Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL. pre-booster and one month after booster vaccination
See also
  Status Clinical Trial Phase
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00153556 - Study to Eliminate Hib Carriage in Rural Alaska Native Villages Phase 4
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Completed NCT01983540 - Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT00401531 - Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants Phase 3
Completed NCT00376779 - Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age Phase 2
Completed NCT00831311 - Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants Phase 2
Completed NCT00254917 - Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Phase 4
Completed NCT01457547 - Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Phase 4
Completed NCT01453998 - Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Phase 2
Completed NCT01449812 - Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Phase 3
Completed NCT00808392 - Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b Phase 3
Completed NCT00307567 - Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 Phase 2
Completed NCT00323050 - Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects Phase 3
Completed NCT00325156 - Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Phase 4